Roche undertakes to invest $ 50 billion in manufacturing and research infrastructure in the United States around the next five years, which makes the pharmaceutical giant into the last company to present a boost of capital expenses while drug manufacturers prepare for the expected work mole.
The administration is still working on the details on how to apply tariffs to pharmaceutical products. But pharmaceutical companies could avoid them by making more of their medications in the United States
Roche based in Basel, based in Switzerland, currently maintains 13 manufacturing and 15 R&D sites in the USA. Through its pharmaceutical and diagnostic divisions. These sites use more than 25,000. The American presence of Roche includes the subsidiary Genentech, based in South San Francisco, and its Diagnostic Division of Roche, which maintains the headquarters of North America in Indianapolis.
The new Roche capital investment plans announced on Tuesday will expand certain Roche sites and some new ones will add. The new planned sites include a gene manufacturing installation in Pennsylvania, a glucose monitor manufacturing site in Indiana and a new R&D center in Massachusetts. The research site will work in artificial intelligence and will also serve as a center for cardiovascular, renal and metabolism R&D. Last month, Roche announced that he would exhibit this 30,000 square feet site on the Harvard Business Research Campus in Boston.
A new 900,000 square feet manufacturing center is also planned for medication weight loss, but the location remains without revealing. Roche joined the growing group of companies that developed obesity measurements with their acquisition of Carmot Therapeutics of $ 2.7 billion in 2023, which brought injectable and oral metabolic medications in the clinical stage. Last month, Roche reached a $ 1.65 billion agreement to associate in the development of a drug for pharmaceutical obesity of Zealand that pursues a different objective from the weight mediations currently greed by greedy. The terms of the agreement make Roche responsible for manufacturing and supplying that engineering peptide, Petrelintide.
Once the new and expanded manufacturing capacity is put online, Roche said that the company will export more US medications. UU. To import the country. But given the deadlines to build a pharmaceutical manufacturing infrastructure, that export surplus is one year away. Roche said that his diagnostic division already has an export surplus from the United States.
“Roche is a Swiss company with a strong inheritance in more than 130 countries worldwide,” said Roche Group CEO, Thomas Schinecker, in a prepared statement. “Today’s announced investments underline our long -standing commitment to research, development and manufacturing in the United States”
Roche’s manufacturing plans follow the capital expenses ads of several of its large pharmaceutical fellow. In February, Eli Lilly announced Onking Capital Investments in Indiana and other parts of the United States more than $ 50 billion.
At the beginning of March, Merck announced the opening of a vaccine manufacturing site of $ 1 billion in Durham, North Carolina. Shortly after, Johnson and Johnson said it would invest more than $ 55 billion in manufacturing and R&D infrastructure in the United States over the next four years. Earlier this month, Novartis announced plans to spend $ 23 billion to expand its manufacturing and R&D infrastructure based on the next five years.
Photo: Giuseppe Aresu/Bloomberg, through Getty Images